Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
APS Industrial expands regional footprint with Control Technologies acquisition
APS Industrial (APS) is expanding its regional presence through the acquisition of Albury-based Control Technologies, a move the industrial products supplier said will strengthen its local service capability and support further investment in warehousing, stockholding and technical support.
